180 related articles for article (PubMed ID: 31851570)
1. Public health and economic impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Mexico.
Ruiz-Palacios GM; Beigel JH; Guerrero ML; Bellier L; Tamayo R; Cervantes P; Alvarez FP; Galindo-Fraga A; Aguilar-Ituarte F; Lopez JG
Hum Vaccin Immunother; 2020 Apr; 16(4):827-835. PubMed ID: 31851570
[TBL] [Abstract][Full Text] [Related]
2. Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay.
Arbo A; Martinez-Cuellar C; Vazquez C; Bellier L; Adorno C; Dibarboure H; Lopez JG; Petitjean A; Bianculli P
Hum Vaccin Immunother; 2022 Nov; 18(5):2069974. PubMed ID: 35543602
[TBL] [Abstract][Full Text] [Related]
3. Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia.
Jamotte A; Chong CF; Manton A; Macabeo B; Toumi M
BMC Public Health; 2016 Jul; 16():630. PubMed ID: 27449665
[TBL] [Abstract][Full Text] [Related]
4. From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain.
Crépey P; Redondo E; Díez-Domingo J; Ortiz de Lejarazu R; Martinón-Torres F; Gil de Miguel Á; López-Belmonte JL; Alvarez FP; Bricout H; Solozabal M
PLoS One; 2020; 15(5):e0233526. PubMed ID: 32437476
[TBL] [Abstract][Full Text] [Related]
5. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe.
Uhart M; Bricout H; Clay E; Largeron N
Hum Vaccin Immunother; 2016 Sep; 12(9):2259-68. PubMed ID: 27166916
[TBL] [Abstract][Full Text] [Related]
6. Cost Utility of Switching From Trivalent to Quadrivalent Influenza Vaccine in Turkey.
Amiche A; Tanriover MD; Bellier L; Ugur B; Akin L
Value Health Reg Issues; 2021 Sep; 25():15-22. PubMed ID: 33485248
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme.
Bellier L; Petitjean A; Sarazu T; Tresierra J; Lopez JG
Vaccine; 2021 Jul; 39(30):4144-4152. PubMed ID: 34130885
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.
Mennini FS; Bini C; Marcellusi A; Rinaldi A; Franco E
Hum Vaccin Immunother; 2018; 14(8):1867-1873. PubMed ID: 29708843
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT
BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131
[TBL] [Abstract][Full Text] [Related]
10. Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis.
Bianculli PM; Bellier L; Mangado IO; Pérez CG; Mieres G; Lazarov L; Petitjean A; Dibarboure H; Lopez JG
Hum Vaccin Immunother; 2022 Nov; 18(5):2050653. PubMed ID: 35344679
[TBL] [Abstract][Full Text] [Related]
11. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.
de Boer PT; Crépey P; Pitman RJ; Macabeo B; Chit A; Postma MJ
Value Health; 2016 Dec; 19(8):964-975. PubMed ID: 27987647
[TBL] [Abstract][Full Text] [Related]
13. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine.
Reed C; Meltzer MI; Finelli L; Fiore A
Vaccine; 2012 Mar; 30(11):1993-8. PubMed ID: 22226861
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
Yang MC; Tan EC; Su JJ
Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
[TBL] [Abstract][Full Text] [Related]
15. A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
Mullikin M; Tan L; Jansen JP; Van Ranst M; Farkas N; Petri E
Infect Dis Ther; 2015 Dec; 4(4):459-87. PubMed ID: 26350238
[TBL] [Abstract][Full Text] [Related]
16. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland.
Nagy L; Heikkinen T; Sackeyfio A; Pitman R
Pharmacoeconomics; 2016 Sep; 34(9):939-51. PubMed ID: 27423657
[TBL] [Abstract][Full Text] [Related]
17. Inactivated quadrivalent split-virus seasonal influenza vaccine (Fluarix® quadrivalent): a review of its use in the prevention of disease caused by influenza A and B.
McKeage K
Drugs; 2013 Sep; 73(14):1587-94. PubMed ID: 24022123
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E
Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078
[TBL] [Abstract][Full Text] [Related]
19. Retrospective public health impact of a quadrivalent influenza vaccine in the United States.
Crépey P; de Boer PT; Postma MJ; Pitman R
Influenza Other Respir Viruses; 2015 Aug; 9 Suppl 1(Suppl 1):39-46. PubMed ID: 26256294
[TBL] [Abstract][Full Text] [Related]
20. Quadrivalent influenza vaccines in low and middle income countries: Cost-effectiveness, affordability and availability.
Hendriks J; Hutubessy RCW; Grohmann G; Torelli G; Friede M; Kieny MP
Vaccine; 2018 Jun; 36(28):3993-3997. PubMed ID: 29866617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
